Depression, Major Depressive Disorder
Conditions
Keywords
REL-1017, esmethadone, Relmada, antidepressant, NMDA receptor antagonist, Depression
Brief summary
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other effective therapy and are not eligible for other clinical trials with esmethadone (REL-1017).
Detailed description
The Expanded Access Program (EAP) is intended to provide pre-approval access to esmethadone (REL-1017) for eligible patients who suffer from a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) as determined by the treating physician and have no satisfactory treatment options. This program is open in the United States and operates under the Individual Patient (also referred to as Single Patient) IND expanded access route in which the patient's treating physician serves as the sponsor. Expanded access requests must be from the patient's treating physicians and submitted according to the Relmada EAP policy at https://www.relmada.com/our-portfolio/eap.
Interventions
DRUGREL-1017
REL-1017 tablet
Sponsors
Relmada Therapeutics, Inc.
Sponsor-Investigator
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients who may potentially benefit from treatment with esmethadone (REL-1017) as determined by the treating physician. * Have undergone appropriate standard treatments without success and in the opinion of the treating physician no comparable or satisfactory alternative treatment is available to treat the disease or condition. * Are ineligible or unable to participate in any ongoing clinical study of the investigational product. * Condition for which, in the opinion of the treating physician, there is sufficient evidence of a potential benefit from the use of the investigational product, and that potential benefit outweighs the known or anticipated risks.
Exclusion criteria
* History or presence of clinically significant health conditions which in the opinion of the Investigator would negatively impact the safety of the participant. * History of QTc prolongation. * History of allergy or hypersensitivity to methadone or related drugs. * Pregnant or planning to become pregnant. * Breast-feeding or planning to breast-feed.
Contacts
STUDY_DIRECTORMarco Pappagallo, MD
Relmada Therapeutics
Outcome results
None listed